{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-012293","form_type":"8-K","ticker":"BPTH","cik":"0001133818","company_name":"BIO-PATH HOLDINGS, INC.","filed_at":"2024-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.257513+00:00","generated_at":"2026-05-31T08:57:21.352207+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Bio-Path posts Q2 2024 net loss of $1.9M; cash position improves to $4.0M","bullets":["Net loss of $1.9M ($1.16 per share) vs $4.2M ($10.64 per share) in Q2 2023.","Cash $4.0M at June 30, 2024, up from $1.1M at Dec 31, 2023; operating cash burn $4.3M.","Closed $4.0M private placement in June: 1.8M shares + warrants at $2.21/share.","R&D expense down to $1.9M from $3.1M; G&A flat at $1.2M.","Presented interim Phase 2 data for prexigebersen in AML at ASCO and EHA."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-012293","json":"https://secwatch.observer/filing/0001558370-24-012293.json","markdown":"https://secwatch.observer/filing/0001558370-24-012293.md","text":"https://secwatch.observer/filing/0001558370-24-012293.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024012293/0001558370-24-012293-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024012293/bpth-20240815x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:57:21.352207+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}